- · The credibility of the vaccine has been portrayed in a study, published in the Lancet journal
- · The researchers have also maintained that any considerations for the booster shots must take into account the global Covid-19 vaccine supply scenario, as people from many countries have not yet received the primary series of vaccines
- · The researchers have also mentioned the fact that Delta became the dominant strain during the study period
A recent study by the Lancet journal has shown that the Pfizer vaccine is highly effective against the Covid-19 disease and prevents infections of different variants including Delta after a person has gone through both doses of the shot. The assumed rate of effectiveness of the vaccine is nearly 90 percent.
Researchers have discovered that the effectiveness of Pfizer did not diminish over the period of research. This stands in contradistinction to the other vaccines, the effectiveness of which against all SARS-CoV-2 variants have declined within a month’s time of both the doses being jabbed. Sara Tarof from Kaiser Permanente, who happens to be the lead author of the study, has said, “Our study confirms that vaccines are a critical tool for controlling the pandemic and remain highly effective in preventing severe disease and hospitalization, including from the Delta and other variants of concern.”
She has also stated that protection against infection decline in the months following a second dose. In light of the fact that people in many countries around the world have failed to receive even the primary series of vaccination, the researchers have mentioned that any considerations for the booster shots must take into account the global Covid-19 vaccine supply.
3,436,957 electronic health records from the Kaiser Permanente Southern California were analyzed by the research team at a time period between December 4, 2020, and August 8, 2021, in order to examine the effectiveness of the vaccine against SARS-CoV-2 infection and hospitalization issues associated with Covid. The percentage of people infected with SARS-CoV-2 during the study period amounts to 5.4. 6.6 percent of people were hospitalized among the ones infected. Three to four months was the average time for being fully vaccinated.
According to the study, the effectiveness of the two doses of Pfizer against the Delta variant infections at one month was 93 percent, whereas, it declined to 53 percent within a time period of four months. In the case of other variants, the effectiveness of both doses at one month was 97 percent, which fell to 67 percent after four months.
The researchers have also stated that as Delta became the dominant strain amid the study period, analyses with prolonged follow-up are needed, in order to estimate the warning imposed by the variant compared to the other strains.
Luis Jodar, the senior vice-president and chief medical officer, Pfizer Vaccines, has said, “Our variant-specific analysis clearly shows that the BNT162b2 vaccine is effective against all current variants of concern, including Delta.” He also stated, “Covid-19 infections in people who have received two vaccine doses are most likely due to waning and not caused by delta or other variants escaping vaccine protection.”